Overview

Acute cholangitis is a potentially life-threatening condition in which infection and inflammation involve the bile ducts, usually in the setting of biliary obstruction or impaired drainage (for example, choledocholithiasis, strictures, malignancy, or dysfunctional stents). Because illness severity spans a wide spectrum—from relatively stable patients who respond quickly to antibiotics to those with shock, organ failure, and need for urgent source control—international consensus documents have emphasized standardized diagnostic criteria and severity stratification.

The Tokyo Guidelines 2018 (TG18) updated the diagnostic approach for acute cholangitis and reaffirmed use of the TG13 severity grading system for classifying disease as mild (Grade I), moderate (Grade II), or severe (Grade III). The CalcMD calculator on this page applies that severity logic: it first checks for Grade III organ/system dysfunction; if none are present, it counts moderate (Grade II) criteria; otherwise the case falls into the mild (Grade I) category.

Why severity classification matters clinically

Acute cholangitis management integrates three pillars: antimicrobial therapy, supportive care and resuscitation, and, when indicated, biliary drainage to relieve obstruction and control the infectious source. Severity assessment helps teams anticipate complications, allocate monitoring intensity, coordinate specialty involvement (gastroenterology, interventional radiology, surgery, critical care), and time interventions. TG18 highlighted that big-data analyses supported the clinical utility of the TG13 criteria, including observations that certain severity patterns were associated with outcomes and that early or urgent biliary drainage appeared especially relevant for some patient subsets—underscoring why consistent grading at the bedside is useful even when individual decisions remain context-dependent.

Diagnostic criteria: the TG18 A / B / C structure

TG18 organizes diagnosis into three domains that reflect the typical pathophysiology: systemic inflammation, cholestasis, and imaging evidence of biliary disease.

A. Systemic inflammation

• Clinical evidence such as fever and/or shaking chills.
• Laboratory evidence of an inflammatory response (for example, leukocytosis or leukopenia, elevated C-reactive protein, or other markers consistent with systemic inflammation in the clinical context).

Inflammatory markers are sensitive but not specific; they must be interpreted alongside cholestatic and imaging data and the overall clinical syndrome.

B. Cholestasis

• Jaundice or hyperbilirubinemia.
• Abnormal hepatobiliary enzymes such as alkaline phosphatase, gamma-glutamyl transferase, and/or transaminase elevations—often expressed in guideline materials relative to local upper limits of normal.

Cholestatic patterns support biliary involvement, but similar laboratory findings can occur in other hepatobiliary disorders; correlation with history, examination, and imaging remains essential.

C. Imaging evidence

• Biliary dilatation or other imaging features indicating biliary pathology.
• Etiologic clues on imaging such as stones, strictures, masses, or complications related to prior biliary instrumentation.

Ultrasound, CT, and MRI/MRCP each have roles depending on availability, patient stability, and suspected etiology. Imaging not only supports diagnosis but also informs the safest and fastest route to drainage when needed.

How criteria combine: suspected versus definite diagnosis

In the TG18 framework, a suspected diagnosis is supported when there is evidence of systemic inflammation plus at least one feature from either cholestasis or imaging. A definite diagnosis is supported when there is at least one criterion from each of A, B, and C. Clinical judgment still applies: comorbidities, atypical presentations (especially in older adults or immunocompromised hosts), and competing diagnoses may require broader evaluation.

Helpful clinical context—though not a formal A/B/C “checkbox” in the same sense—includes right upper quadrant or epigastric pain and a history of gallstone disease, prior biliary surgery, or indwelling biliary hardware, all of which increase pretest probability.

Severity grading: TG13 criteria adopted by TG18

TG18 retained the TG13 severity definitions. The guiding principle is to identify severe disease early by detecting organ/system dysfunction, and to identify moderate disease using a compact set of laboratory and clinical markers when severe features are absent.

Grade III (severe): organ or system dysfunction

Grade III acute cholangitis is defined by the presence of at least one criterion indicating dysfunction across major organ systems. In practice, teams screen for cardiovascular instability requiring vasopressor support, altered consciousness, hypoxemic respiratory failure by severity thresholds, acute kidney injury or oliguria, coagulopathy reflected by prolonged INR, and severe thrombocytopenia. The presence of any such criterion places the patient in the severe category, even if other features appear modest—because the priority shifts to aggressive resuscitation, broad-spectrum therapy, and urgent planning for biliary drainage and intensive care when indicated.

Grade II (moderate): two or more moderate markers

If no Grade III dysfunction is present, Grade II is defined by two or more of the following: marked leukocytosis or leukopenia, high fever, advanced age, hyperbilirubinemia, and hypoalbuminemia. These markers do not individually define moderate disease; the count matters. Moderate classification should prompt heightened monitoring and earlier consideration of biliary drainage strategy, particularly if the patient is not improving with initial medical therapy.

Grade I (mild)

Patients who do not meet Grade III criteria and who have fewer than two Grade II criteria align with Grade I (mild) under this schema. Many such patients can be managed initially with antibiotics and supportive care while arranging definitive management of the underlying biliary problem—but mild classification is not a guarantee of a benign course, and repeat assessment is warranted if new organ dysfunction or additional moderate criteria develop.

How to use this calculator responsibly

The calculator is designed as a structured checklist that mirrors published grading rules:

1. Begin with the Grade III section. If any item is present, the severity output is Grade III regardless of other inputs.
2. If no Grade III items are selected, move to the Grade II section and count how many moderate criteria are present. Two or more yields Grade II.
3. If neither rule is met, the output is Grade I.

This sequencing matches the clinical priority of detecting life-threatening physiology first. The tool does not, by itself, establish the diagnosis of acute cholangitis; it assumes you are evaluating a patient in whom acute cholangitis is being considered or has been diagnosed, and you are standardizing severity documentation and communication across team members.

Integration with management themes (antibiotics, drainage, monitoring)

Antibiotics should be chosen to cover enteric Gram-negative organisms and common biliary pathogens, adjusted for local resistance patterns, allergies, renal function, and prior cultures when available. Source control via biliary drainage is central when obstruction persists or the patient deteriorates; modality (endoscopic, percutaneous, surgical) depends on anatomy, expertise, coagulation status, and stability. Supportive care includes fluid resuscitation, correction of electrolyte and coagulation abnormalities, hemodynamic monitoring, and escalation to intensive care when Grade III features emerge.

Severity can evolve over hours. A patient classified as Grade I on arrival may develop hypotension, confusion, or worsening hypoxia—triggering reclassification and a change in monitoring and intervention urgency. Likewise, aggressive early treatment may downshift the clinical picture even if initial laboratory abnormalities suggested Grade II.

Limitations of checklist-based grading

• Vasopressor thresholds and organ dysfunction definitions require bedside interpretation; transient hypotension from sedation, bleeding, or arrhythmia may not mean the same thing as septic shock from cholangitis.
• Laboratory cutoffs are useful for standardization but cannot capture every atypical presentation (for example, patients on immunosuppression with blunted fever or leukocyte response).
• Imaging and diagnostic certainty are not modeled in the severity tool; a patient can be “severe” from sepsis with an alternate diagnosis if criteria are misapplied without clinical correlation.
• Institutional pathways, specialist availability, and patient goals of care appropriately modify how criteria translate into action.

Used thoughtfully, Tokyo Guidelines–aligned severity grading improves communication and reduces missed escalation; it should always remain a supplement to—not a substitute for—comprehensive clinical assessment.